Cough And Chest Congestion Maximum Strength Suspension
NDC Package 69676-0077-9
Package Information
Cough And Chest Congestion Maximum Strength (dextromethorphan hbr, guaifenesin) suspension is useshelps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productivetemporarily relieves:cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritantsthe intensity of coughingthe impulse to cough to help you get to sleep Usestemporarily relieves these common cold and flu symptoms:cough due to minor throat and bronchial irritationminor aches and painssore throatheadacherunny nosesneezingtemporarily reduces fevercontrols cough to help you get to sleep. This formulation utilizes a suspension delivery system. Marketed by Genexa Inc., this product is identified by NDC 69676-0077 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 2692302 - acetaminophen 650 MG / dextromethorphan HBr 30 MG / doxylamine succinate 12.5 MG in 20 mL Oral Suspension
- RxCUI: 2692302 - acetaminophen 32.5 MG/ML / dextromethorphan hydrobromide 1.5 MG/ML / doxylamine succinate 0.625 MG/ML Oral Suspension
- RxCUI: 2692302 - acetaminophen 650 MG / dextromethorphan HBr 30 MG / doxylamine succinate 12.5 MG per 20 ML Oral Suspension
- RxCUI: 2692302 - APAP 32.5 MG/ML / dextromethorphan hydrobromide 1.5 MG/ML / doxylamine succinate 0.625 MG/ML Oral Suspension
- RxCUI: 2692303 - dextromethorphan HBr 20 MG / guaiFENesin 400 MG in 20 mL Oral Suspension
Clinical Specifications
- Decreased Respiratory Secretion Viscosity - [PE] (Physiologic Effect)
- Expectorant - [EPC] (Established Pharmacologic Class)
- Increased Respiratory Secretions - [PE] (Physiologic Effect)
- Sigma-1 Agonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Receptor Agonists - [MoA] (Mechanism of Action)
- Uncompetitive N-methyl-D-aspartate Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Uncompetitive NMDA Receptor Antagonists - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 69676 - Genexa Inc.
- 69676-0077 - Cough And Chest Congestion Maximum Strength
- 69676-0077-9 - 177 mL in 1 BOTTLE, PLASTIC
- 69676-0077 - Cough And Chest Congestion Maximum Strength
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69676-0077-9 identifies a specific commercial package of 177 ml in 1 bottle, plastic of Cough And Chest Congestion Maximum Strength, a human over the counter drug labeled by Genexa Inc.. This suspension is formulated for oral use and contains dextromethorphan hydrobromide; guaifenesin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Genexa Inc. on February 12, 2024. The current certification is valid through December 31, 2026.
How is this Genexa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69676007709. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.
